Neximmune reports fiscal year 2020 financial results and recent updates

Gaithersburg, md., march 31, 2021 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today reported its financial results for 2020 and highlighted recent corporate accomplishments.
NEXI Ratings Summary
NEXI Quant Ranking